Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Price Target at $15.17

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $15.1667.

A number of equities research analysts recently commented on the stock. Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. UBS Group assumed coverage on shares of Amneal Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Finally, Barclays lifted their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th.

Insider Activity

In other news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares in the company, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 17.30% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of AMRX. Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $26,000. Federated Hermes Inc. raised its position in shares of Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the last quarter. Comerica Bank raised its position in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the last quarter. Spire Wealth Management raised its position in shares of Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the last quarter. Finally, Transamerica Financial Advisors LLC raised its position in shares of Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ:AMRX opened at $12.95 on Friday. The company has a market cap of $4.13 billion, a P/E ratio of 34.08 and a beta of 1.32. Amneal Pharmaceuticals has a 52 week low of $7.07 and a 52 week high of $15.42. The company has a 50-day moving average price of $12.61 and a 200 day moving average price of $12.92.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The firm had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. Analysts expect that Amneal Pharmaceuticals will post 0.92 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.